Neuphoria Therapeutics Inc.NEUPEarnings & Financial Report
Nasdaq
Neuphoria Therapeutics Inc is a clinical-stage biopharmaceutical company focused on researching and developing innovative targeted therapies for unmet medical needs in neurological and psychiatric conditions, including anxiety, treatment-resistant depression, and other central nervous system disorders. Its core R&D efforts prioritize delivering safer, more effective treatment options for patient groups with limited existing care alternatives.
Top Holders
| Holder | % Owned | Shares | Change | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | 9.99% | 1.7M | — | 2024-11-14 |
| Apeiron Investment Group Ltd. | 8.90% | 276.5M | — | 2024-10-07 |
| Point72 Asset Management, L.P. | 4.00% | 59.6M | ▼ -4.10pp | 2024-02-14 |
| Lynx1 Capital Management LP | 3.20% | 98.9M | ▼ -4.60pp | 2024-11-14 |
| NOS. of Above Persons | 0.00% | 9.1K | ▼ -8.60pp | 2024-02-14 |
| Biotechnology Value Fund, L.P. | 0.00% | 9.1K | — | 2024-02-14 |
Insider Transactions
Net 90d: +$0 · buys $0 / sells $0Range:
Action:
Role:
No transactions match these filters.